Phase 1 Study of LY573636-sodium in Patients With Essential Thrombocythemia and Acute Myeloid Leukemia.
Phase of Trial: Phase I
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Tasisulam (Primary)
- Indications Acute myeloid leukaemia; Essential thrombocythaemia
- Focus Adverse reactions; Biomarker
- Sponsors Eli Lilly and Company
- 10 Feb 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.